Source:http://linkedlifedata.com/resource/pubmed/id/19475615
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0002085,
umls-concept:C0019721,
umls-concept:C0030705,
umls-concept:C0030956,
umls-concept:C0033684,
umls-concept:C0178539,
umls-concept:C0205263,
umls-concept:C0220847,
umls-concept:C0444669,
umls-concept:C0456387,
umls-concept:C0871261,
umls-concept:C1441547,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
pubmed:issue |
7
|
pubmed:dateCreated |
2009-6-2
|
pubmed:abstractText |
C35-44 peptide is a well known HLA-A2-restricted CTL epitope originating from hepatitis C virus (HCV) core protein. It was reported that the majority of HCV positive patients had significant levels of serum IgG specific to this peptide. This study addressed whether C35-44 peptide could induce CTL activity restricted to various HLA class IA alleles or could not. This peptide demonstrated binding activity to HLA-A*2402, -A*2601, -A*3101, and -A*3303 molecules, but not to HLA-A*1101 by means of stabilization assay. This peptide also induced CTL activity restricted to each of them, except HLA-A11(+) peripheral blood mononuclear cells from HCV 1b(+) patients by means of (51)Cr-release assay. With regard to HLA-A2 subtypes, this peptide demonstrated binding activity to HLA-A*0201 and -A*0206, but not to -A*0207 molecules. Furthermore, this peptide induced CTL activity from both the patients and healthy donors with all the HLA class IA molecules mentioned above by means of interferon-gamma production assay. These results may provide new insights for the development of a novel peptide vaccine against HCV compatible with various HLA class IA types.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Core Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/nucleocapsid protein, Hepatitis C...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1096-9071
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2009 Wiley-Liss, Inc.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
81
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1232-40
|
pubmed:meshHeading |
pubmed-meshheading:19475615-Adult,
pubmed-meshheading:19475615-Aged,
pubmed-meshheading:19475615-Alleles,
pubmed-meshheading:19475615-Cytotoxicity, Immunologic,
pubmed-meshheading:19475615-Female,
pubmed-meshheading:19475615-Hepacivirus,
pubmed-meshheading:19475615-Hepatitis C,
pubmed-meshheading:19475615-Histocompatibility Antigens Class I,
pubmed-meshheading:19475615-Humans,
pubmed-meshheading:19475615-Interferon-gamma,
pubmed-meshheading:19475615-Male,
pubmed-meshheading:19475615-Middle Aged,
pubmed-meshheading:19475615-Peptides,
pubmed-meshheading:19475615-Protein Binding,
pubmed-meshheading:19475615-T-Lymphocytes,
pubmed-meshheading:19475615-Viral Core Proteins
|
pubmed:year |
2009
|
pubmed:articleTitle |
A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles.
|
pubmed:affiliation |
Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|